Diabetic retinopathy
Advancing antibody targets to treat diabetic retinopathy
in partnership with Abcellera

Our Mission

Angios aims to prevent or treat leading causes of diabetes related blindness.  

About diabetes-related blindness

Diabetic retinopathy is one of the leading global causes for blindness in patients aged 50+
Diabetes causes misfunction of blood vessels, which results in problems in many organs. In the eye, the blood vessels that support the retina with oxygen start to leak fluid. This causes two related diseases – diabetic retinopathy and diabetic macular edema.

In severe cases, the fluid leakage distorts vision and can even lead to complete blindness.

The current situation

The standard of care for diabetic retinopathy and diabetic macular edema is insufficient.
Current treatments help to delay disease progression in only half of all patients. They also require patients to maintain a strict monthly / bi-monthly treatment schedule, resulting in low compliance.  

At Angios we aim to identify therapeutics that act on a broader patient population and lead to more durable treatment responses.

Our approach

We are developing novel antibodies for the treatment of diabetic retinopathy and diabetic macular edema.
To this end, we partnered with AbCellera Biologics (NASDAQ: ABCL), a global leader in antibody drug development. This partnership will accelerate our efforts of bringing novel treatments for diabetes-related blindness to the clinic.